Nondividend payers, such as the fund's positions in Vertex Pharmaceuticals and Royal Caribbean Group, are capped at 5%. While the strategy has excluded alcohol or tobacco companies previously ...

Global drugmakers and MedTech companies bounced back after U.S. President Donald Trump issued a 90-day pause on reciprocal ...

The NICE-Vertex saga continued this month with Vertex ... During the three-hour hearing in Washington, DC, the pharma bosses said that prices had to remain high and pharmacy benefit managers ...

It is with great honor that the Chester County Opportunities Industrialization Centers (Chester County OIC) welcomes its ...

Though pharmaceuticals have been exempt from the tariffs announced ... A group of senators led by Washington Democrat Maria Cantwell and Iowa Republican Charles Grassley is also trying to fight the ...

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...

Vertex Pharmaceuticals Inc. closed 8.54% short of its 52-week high of $519.88, which the company achieved on November 8th.

Will these developments be enough to sustain the rally? Let's discuss whether Vertex Pharmaceuticals stock is a buy now. The past year has been transformative for Vertex, marked by the launch of ...

Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $462 from $459 and keeps an Equal Weight rating on the ...

The stock's rise snapped a three-day losing streak.